TOOKAD® Soluble vascular-targeted photodynamic (VTP) therapy: Determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer

BJU International

Volumn 112, Issue 6, 2013, Pages 766-774

  Azzouzi, Abdel Rahmène ^a   Barret, Eric ^b   Moore, Caroline M ^c   Villers, Arnaud ^d   Allen, Clare ^c   Scherz, Avigdor ^e   Muir, Gordon ^f   De Wildt, Michel ^g   Barber, Neil J ^h   Lebdai, Souhil ^a   Emberton, Mark ^c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g CATHARINA HOSPITAL   (Netherlands)

^h FRIMLEY PARK HOSPITAL   (United Kingdom)

Author keywords

focal therapy; photodynamic; prostate; TOOKAD Soluble; vascular; VTP

Indexed keywords

GLASS FIBER; LIVER ENZYME; PADELIPORFIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CONSTIPATION; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOPROSTATITIS; DIODE LASER; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DYSURIA; EPIDIDYMO ORCHITIS; FOLLOW UP; GENERAL ANESTHESIA; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISCHEMIC OPTIC NEUROPATHY; LIGHT INTENSITY; MAJOR CLINICAL STUDY; MALE; MALE GENITAL SYSTEM DISEASE; MULTICENTER STUDY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATIENT SAFETY; PERINEAL PAIN; PERINEUM; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SIZE; PROSTATE TUMOR; PROSTATITIS; QUALITY OF LIFE; SELF REPORT; SINGLE DRUG DOSE; THERAPY EFFECT; TISSUE NECROSIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE RETENTION; VASCULAR TARGETED PHOTODYNAMIC THERAPY;

FOCAL THERAPY; PHOTODYNAMIC; PROSTATE; TOOKAD® SOLUBLE; VASCULAR; VTP;

AGED; BACTERIOCHLOROPHYLLS; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOTOCHEMOTHERAPY; PROSTATE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84884260303     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12265     Document Type: Article

References (19)

1. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-1123
2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR,. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178: S14-19
3. Klotz L,. Active surveillance for prostate cancer: a review. Curr Urol Rep 2010; 11: 165-171
4. Parker WR, Montgomery JS, Wood DP Jr,. Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner? Curr Opin Urol 2009; 19: 303-308
5. Wilt TJ, Brawer MK, Jones KM, et al.; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203-213
6. Heidenreich A, Bellmunt J, Bolla M, et al.; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
7. Nomura T, Mimata H,. Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer. Adv Urol 2012; 2012: 1-8
8. Mazor O, Brandis A, Plaks V, et al. WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem Photobiol 2005; 81: 342-351
9. ®), in normal canine prostate and spontaneous canine prostate cancer. Lasers Surg Med 2005; 36: 390-397
10. Trachtenberg J, Weersink RA, Davidson SR, et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 2008; 102: 556-562
11. Trachtenberg J, Bogaards A, Weersink RA, et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 2007; 178: 1974-1979
12. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454-1457
13. ®): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer 2003; 104: 782-789
14. Brandis A, Mazor O, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A,. Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: synthesis, solubility, phototoxicity and the effect of serum proteins. Photochem Photobiol 2005; 81: 983-993
15. Ashur I, Goldschmidt R, Pinkas I, et al. Photocatalytic generation of oxygen radicals by the water-soluble bacteriochlorophyll derivative WST11, noncovalently bound to serum albumin. J Phys Chem A 2009; 113: 8027-8037
16. ®. PLoS One 2010; 5: e10282
17. ® Soluble WST11. Phys Med Biol 2011; 56: 4771-4783
18. Choo R, Danjoux C, Morton G, et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 2007; 67: 1614-1620
19. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13: 622-633